This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
UK Index Banks and Housebuilders - Could be sensitive to day's release of UK Net Consumer Credit data. (Source: Reuters)
SSE (SSE) - SSE's retail division’s merger with nPower’s Innogy got provisional CMA approval; customers have plenty of choice, switching at highest in decades, deadline for final report 22 Oct. New listing on-track for Mar 2019. Closing price: 1,250.5p (Source: DowJones Newswires)
AstraZeneca (AZN) - gets EU approval (US approved Oct 2017) for Bydureon BCise device for T2 diabetes. Closing price: 5,889p (Source: DowJones Newswires)
Hays (HAS) - FY net fees +12% YoY (Germany new record +16% but UK +2%), operating profit +15%, pre-tax +17%, dividends +18% (core + special). Closing price: 202.8p (Source: Company Newswires)
Hunting (HTG) - H1 revenue +39% YoY, underlying EBITDA +510%, op. profit swings positive on higher prices. Resumes dividend with 4c. Outlook stable, but potential headwinds from steel trading tariffs. Closing price: 758.5p (Source: Company Newswires)
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| STANDARD CHARTERED | STAN | -0.7% | 0.9% | -1.4% |
| BARRATT DEVELOPMENTS | BDEV | -0.1% | 1.1% | -1.0% |
| BELLWAY | BWY | -0.7% | 0.4% | -2.0% |
| BOVIS HOMES | BVS | -0.1% | 0.8% | -1.1% |
| PERSIMMON | PSN | 0.6% | 1.7% | -0.2% |
| TAYLOR WIMPEY | TW/ | -0.1% | 1.4% | -0.4% |
| PETROFAC | PFC | -0.9% | 2.9% | -2.2% |
| IQE | IQE | -0.2% | 0.8% | -8.9% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.
Prepared by Michael van Dulken, Head of Research